PTC Therapeutics, Inc. (PTCT) Q4 2013 Earnings Results

PTC Therapeutics Misses on EPS — Stock Down 1.33%

PTC Therapeutics reported a larger-than-expected loss for the quarter, which contributed to a 1.33% decline in stock price. The lack of revenue figures and guidance adds to investor uncertainty. The management's cautious tone suggests that the company may face ongoing challenges in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.75	N/A	-28.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current financial outlook. They did not provide any updates on future guidance, indicating uncertainty.

Management did not provide specific revenue guidance for the upcoming quarters.

The company acknowledged challenges in achieving profitability.

PTC Therapeutics Misses on EPS — Stock Down 1.33%

Key numbers

Management commentary

PTC Therapeutics, Inc.

More earnings this week

PTC Therapeutics Misses on EPS — Stock Down 1.33%

Key numbers

Management commentary